Groundbreaking Blood Test for Cancer Detection and Monitoring Now Available in Germany

A new tumor-informed circulating-tumor DNA (ctDNA) blood test, HPH MRD, has been made available in Germany by MVZ HPH Institute for Pathology and Hematopathology GmbH. Developed in collaboration with Haystack Oncology, a subsidiary of Quest Diagnostics, the test utilizes Haystack MRD technology to detect ultralow levels of ctDNA with exceptional sensitivity and specificity, enabling the reliable identification of residual or recurrent disease. The HPH MRD test leverages whole-genome sequencing to analyze a patient's tumor tissue and design individualized patient panels, potentially providing greater insight into ctDNA levels than conventional methods.

Key Takeaways:

• HPH MRD is a tumor-informed circulating-tumor DNA (ctDNA) blood test for detecting minimal residual disease (MRD) in patients diagnosed with solid tumor cancers.
• The test utilizes Haystack MRD technology, developed by Haystack Oncology, a subsidiary of Quest Diagnostics.
• HPH MRD testing will be performed in MVZ HPH Institute for Pathology and Hematopathology GmbH's laboratories in Hamburg, Germany.
• The test enables earlier and more accurate detection of residual or recurrent disease, providing clinicians with the ability to make timely, evidence-based treatment decisions with confidence.
• ctDNA MRD testing is rapidly transforming cancer care by detecting molecular evidence of disease and providing insights that often remain undetectable with standard imaging methods.
• The HPH MRD test is an in-house test manufactured by MVZ HPH Institute for Pathology and Hematopathology GmbH, making use of Haystack MRD technology, and is available through a license from Haystack Oncology.

Statistics:

• The HPH MRD test utilizes whole-genome sequencing to analyze a patient's tumor tissue and design individualized patient panels.
• The test enables the sensitive identification of residual or recurrent disease with exceptional sensitivity and specificity.
• Current testing and data will remain with HPH in Germany, facilitating compliance with data protection and regulatory standards.
• The HPH MRD test can provide potentially faster results compared to standard testing methods.
• HPH MRD testing is available in the company's laboratories in Hamburg, Germany, providing local availability and ensuring improved clinical implementation.

Sources:

• MVZ HPH Institute for Pathology and Hematopathology GmbH
• Haystack Oncology
• Quest Diagnostics
• Public Relations Newswire (Oct. 17, 2025)
• Prof. Markus Tiemann, CEO, MVZ HPH Institute for Pathology and Hematopathology GmbH
• Dan Edelstein, Vice President & General Manager and co-founder of Haystack Oncology